Altimmune, Inc.
A clinical-stage biopharmaceutical company developing pemvidutide, a balanced GLP-1 and glucagon dual receptor agonist in late-stage trials for fatty-liver disease (MASH), alcohol use disorder, and alcohol-associated liver disease. It began in 1997 as vaccine maker Vaxin Inc. before renaming to Altimmune in 2015, and its early work included NasoVAX, a needle-free intranasal flu vaccine.
Granted 117.0K
Granted 53.1K
Granted 44.4K
Bought 47.5K
Granted 18.8K · Bought 15.0K
Bought 21.7K
Bought 5.0K
Bought 500
Bought 527
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Garg Vipin KDirector · 7 transactions | +16.8% | 424.5K | 117.0K | — | — |
| Roberts M ScotChief Scientific Officer · 9 transactions | +52.3% | 112.8K | 53.1K | — | — |
| Jordt Raymond MChief Business Officer · 7 transactions | +93.3% | 70.1K | 44.4K | — | — |
| Durso Jerome BenedictPresident and CEO, Director · 3 transactions | — | 47.5K | — | 47.5K | — |
| Weaver Gregory LChief Financial Officer · 4 transactions | +280.8% | 38.1K | 18.8K | 15.0K | — |
| Gill JohnDirector · 2 transactions | +683.1% | 21.7K | — | 21.7K | — |
| Pisano WayneDirector · 1 transaction | +58.8% | 13.5K | — | 5.0K | — |
| Sohn Catherine A.Director · 1 transaction | +50% | 1.5K | — | 500 | — |
| Jorkasky DianeDirector · 1 transaction | — | 527 | — | 527 | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: +90.2K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.